JP2011520770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520770A5 JP2011520770A5 JP2010544375A JP2010544375A JP2011520770A5 JP 2011520770 A5 JP2011520770 A5 JP 2011520770A5 JP 2010544375 A JP2010544375 A JP 2010544375A JP 2010544375 A JP2010544375 A JP 2010544375A JP 2011520770 A5 JP2011520770 A5 JP 2011520770A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- alkyl
- acceptable salt
- aryl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims 19
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 19
- 125000004104 aryloxy group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 125000002947 alkylene group Chemical group 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 125000004450 alkenylene group Chemical group 0.000 claims 5
- 150000001721 carbon Chemical group 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- -1 hydroxy, methyl Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 *c1c(*)[n](*c(c2c(*)c(*)c3*)c(*)[n](*)c2[n+]3[O-])c2c1c(*)c(*)c(*)n2 Chemical compound *c1c(*)[n](*c(c2c(*)c(*)c3*)c(*)[n](*)c2[n+]3[O-])c2c1c(*)c(*)c(*)n2 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2323708P | 2008-01-24 | 2008-01-24 | |
| US61/023,237 | 2008-01-24 | ||
| PCT/US2009/031093 WO2009094287A1 (en) | 2008-01-24 | 2009-01-15 | Iap inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011520770A JP2011520770A (ja) | 2011-07-21 |
| JP2011520770A5 true JP2011520770A5 (enExample) | 2012-03-01 |
Family
ID=40901405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010544375A Abandoned JP2011520770A (ja) | 2008-01-24 | 2009-01-15 | Ｉａｐ阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110288116A1 (enExample) |
| EP (1) | EP2242362A4 (enExample) |
| JP (1) | JP2011520770A (enExample) |
| KR (1) | KR20100119768A (enExample) |
| CN (1) | CN101951766A (enExample) |
| AU (1) | AU2009206588A1 (enExample) |
| BR (1) | BRPI0906785A2 (enExample) |
| CA (1) | CA2712604A1 (enExample) |
| IL (1) | IL207066A0 (enExample) |
| MX (1) | MX2010007948A (enExample) |
| WO (1) | WO2009094287A1 (enExample) |
| ZA (1) | ZA201005618B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
| MY159958A (en) | 2009-12-18 | 2017-02-15 | Idenix Pharmaceuticals Inc | 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors |
| UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
| UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| EP2879707A4 (en) * | 2012-08-01 | 2016-05-11 | Tetralogic Pharm Corp | Combination therapy |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| CN115368356B (zh) | 2013-12-20 | 2025-05-09 | 阿斯特克斯治疗有限公司 | 双环杂环化合物及其治疗用途 |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| CN111247161B (zh) * | 2017-11-13 | 2021-12-31 | 正大天晴药业集团股份有限公司 | 用作iap抑制剂的smac模拟物及其用途 |
| US20220175917A1 (en) * | 2019-03-07 | 2022-06-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combination of iap inhibitor and immune checkpoint inhibitor |
| WO2020228642A1 (zh) * | 2019-05-10 | 2020-11-19 | 正大天晴药业集团股份有限公司 | 一种用作iap抑制剂的smac模拟物的结晶及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1933847A (zh) * | 2004-01-16 | 2007-03-21 | 密歇根大学董事会 | Smac肽模拟物及其应用 |
| PL2253614T3 (pl) * | 2004-04-07 | 2013-03-29 | Novartis Ag | Inhibitory IAP |
| WO2006010118A2 (en) * | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
| EA012810B1 (ru) * | 2005-02-25 | 2009-12-30 | Тетралоджик Фармасеутикалс | Димерные ингибиторы ингибиторов белков апоптоза (iap) |
| US20070203749A1 (en) * | 2005-08-09 | 2007-08-30 | Sri Chunduru | Business methods for compounds for treatment of proliferative disorders |
-
2009
- 2009-01-15 MX MX2010007948A patent/MX2010007948A/es not_active Application Discontinuation
- 2009-01-15 AU AU2009206588A patent/AU2009206588A1/en not_active Abandoned
- 2009-01-15 EP EP09703244A patent/EP2242362A4/en not_active Withdrawn
- 2009-01-15 JP JP2010544375A patent/JP2011520770A/ja not_active Abandoned
- 2009-01-15 CA CA2712604A patent/CA2712604A1/en not_active Abandoned
- 2009-01-15 CN CN200980106206XA patent/CN101951766A/zh active Pending
- 2009-01-15 US US12/863,375 patent/US20110288116A1/en not_active Abandoned
- 2009-01-15 WO PCT/US2009/031093 patent/WO2009094287A1/en not_active Ceased
- 2009-01-15 KR KR1020107018102A patent/KR20100119768A/ko not_active Withdrawn
- 2009-01-15 BR BRPI0906785-0A patent/BRPI0906785A2/pt not_active IP Right Cessation
-
2010
- 2010-07-18 IL IL207066A patent/IL207066A0/en unknown
- 2010-08-05 ZA ZA2010/05618A patent/ZA201005618B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015143542A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| NZ604973A (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2011511095A5 (enExample) | ||
| JP2010540509A5 (enExample) | ||
| JP2014503567A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2011001339A5 (enExample) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| JP2017530171A5 (enExample) | ||
| WO2017061532A1 (ja) | ピリミジン化合物 | |
| RU2015125307A (ru) | Комбинированная терапия | |
| RU2013106754A (ru) | Производное фталазинонкетона, способ его получения и его фармацевтическое применение | |
| JP2016506916A5 (enExample) | ||
| JP2008505167A5 (enExample) | ||
| JP2013535491A5 (enExample) | ||
| NZ700583A (en) | Novel 7-deazapurine nucleosides for therapeutic uses | |
| MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
| JP2023533203A5 (enExample) | ||
| JP2013521291A5 (enExample) | ||
| JP2013520443A5 (enExample) | ||
| RU2016131189A (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА | |
| JP2015512943A5 (enExample) | ||
| EA201300073A1 (ru) | Пиразолохинолины |